Sciele Pharma is buying a $7 million equity stake in Plethora Solutions Holding, which develops and sells sexual dysfunction drugs.

Sciele (NASDAQ: SCRX) also licensed U.S. rights to a male sexual dysfunction drug from Plethora, which is based in the United Kingdom.

Plethora drug candidates include treatment for premature ejaculation, overactive bladder, stress urinary incontinence, interstitial cystitis and gynecological pain.

Financial terms of the deal were not disclosed. Plethora will receive payments based on milestones, such as regulatory approval for the licensed premature ejaculation product, and sales as well as royalties. The drug, which is called PSD502 and is delivered as a metered dose spray, is expected to begin a Phase III clinical trial in the second half of this year.